CML28 is a broadly immunogenic antigen, which is overexpressed in XXXX cells.

@entity1 @entity263 @entity5 @entity2 @entity2631 @entity1778 @entity18907 @entity71013 @entity1860 @entity320 @entity6558
Donor lymphocyte infusion (DLI) reliably induces durable remission in 75-80% of @entity1 with relapsed @entity1860 ( @entity1860 ) after allogeneic hematopoietic stem cell transplantation. To identify immunological targets of the graft-versus- @entity1778 response (GVL) after DLI, we used @entity1860 post-DLI responder sera to screen a @entity1860 cDNA expression library. One of the antigens identified in this screen is a M(r) 28,000 protein, termed CML28. CML28 is identical to @entity71013 , a component of the @entity1 exosome, a multiprotein complex involved in the 3' processing of RNA. Components of the @entity1 exosome include known autoantigens, such as @entity18907 , an autoantibody target in @entity1 with @entity6558 , @entity2631 , or @entity6558 - @entity2631 overlap syndrome. Recombinant CML28-GST fusion protein was purified, and used in Western blot and ELISA to demonstrate the development of a high-titer CML28-specific IgG antibody response in a @entity1 with relapsed @entity1860 who responded to DLI. Northern blotting demonstrated that CML28 is highly expressed in a variety of hematopoietic and @entity5 cell lines, but not in normal hematopoietic tissues or other normal tissue, with the exception of testis. Purified recombinant CML28 was used to generate a CML28-specific murine monoclonal antibody. Western blotting with CML28 monoclonal antibody against whole-cell lysates derived from blood and marrow of normal donors and @entity1 with @entity1778 revealed high expression of this antigen in @entity5 but not in normal samples. Because CML28 was highly expressed in @entity5 cell lines, anti-CML28 responses were also examined in @entity1 with solid @entity5 . By ELISA, we found specific serological responses in 10-33% of @entity1 with @entity2 , @entity320 , and @entity263 . Our studies suggest that immunogenicity of CML28 is likely because of overexpression of this antigen in @entity5 cells. Moreover, given its expression and immunogenicity in a wide variety of @entity5 , CML28 merits additional evaluation as a target for antigen-specific immunotherapy.
